Morning Call May 22
Health Care: Drugs
EntreMed Inc. (ENMD: NASDAQ)
$1.83 -0.02 | -1.08%
05/21/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.83 |
| 52 Week High | 3.73 |
| 52 Week Low | 1.23 |
| Avg. Daily Vol. (Mil) | 0.08 |
| Beta (3 year) | 2.17 |
| Share Related Items | |
| Mkt Cap (Mil) | 49.45 |
| Shares Out (Mil) | 27.02 |
| Float (Mil) | 19.36 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 23.00 |
| Current Ratio | 23.20 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 73.89 |
| Price/Book | 2.80 |
| Price/Cash Flow | -1.90 |
| Per Share Data | |
| Earnings | -0.63 |
| Sales | 0.02 |
| Book Value | 0.65 |
| Cash Flow | -0.97 |
| Business Summary | |
|---|---|
| EntreMed, Inc., is a clinical-stage pharmaceutical company, which develops therapeutic candidates for the treatment of cancer and inflammation. | |
| General Information | |
| 9640 Medical Center Drive
Suite 300 Rockville, MD 20850 |
|
| www.entremed.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 8 | |
| CEO: Dr. Ken Keyong Ren | |
| Short Interest | |
| Current Month (Mil) | 0.06 |
| Previous Month (Mil) | 0.15 |
| Short Interest Ratio (Days) | 1.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -141.40 |
| Return on Investments | -147.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with ENMD
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor6 Drug Stocks Unworthy of B...
- UserBeaver
- Contributor10 Stocks Under $5 Outperfo...
- ContributorStocks Under $5 at Risk of ...
- UserDorkingLad Portfolio 1
- Usersmallbiz
- Usersteves #1
- UserThe Investment Psychologist...
- Userdrweik Portfolio 1
Latest ENMD Headlines from TheStreet
- 7 Stocks Under $10 Making Big Moves Higher 07.05.12 | 02:07 pm
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- 10 Stocks Under $5 Outperforming in 2012 01.31.12 | 05:01 am
- Stocks Under $5 at Risk of Bankruptcy 06.08.11 | 06:06 am
- Biotech Sector Weekly Rewind 11.20.10 | 08:11 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Sprint Nextel, Palm: Early Volume Plays 04.19.10 | 07:04 am
- ThermoGenesis, Power-One: Early Volume Plays 02.05.10 | 07:02 am
- Netlist, EntreMed: Midday Volume Plays 12.14.09 | 02:12 pm
Press Releases for ENMD
- Patent Issued In China For EntreMed's Lead Drug Candidate ENMD-2076 - PR Newswire 05.06.13 | 07:05 am
- Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases - PR Newswire 05.03.13 | 07:05 am
- EntreMed Announces Changes To Board Of Directors And CEO Appointment - PR Newswire 04.05.13 | 07:04 am
- EntreMed To Raise $10.7 Million In Registered Direct Offering - PR Newswire 03.01.13 | 08:03 am
- EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma - PR Newswire 01.23.13 | 07:01 am
- EntreMed Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA To Advance Global Development Strategy - PR Newswire 01.07.13 | 07:01 am
- EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer - PR Newswire 01.04.13 | 07:01 am
- PNAS Publishes Preclinical Results Of EntreMed's 2ME2 For Multiple Sclerosis - PR Newswire 12.04.12 | 01:12 pm
- EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer - PR Newswire 11.26.12 | 07:11 am
- Dana-Farber Cancer Institute's Ursula A. Matulonis, MD Article On EntreMed's ENMD-2076 Published In The European Journal Of Cancer - PR Newswire 09.06.12 | 07:09 am
Partner Headlines for ENMD
- Morning Market Movers - Benzinga 11.26.12 | 09:11 am
- Alexandria Leases to NIH - Analyst Blog - NASDAQ 09.07.12 | 08:09 pm
- China Biotech In Review: GSK Explores All Paths To Increase China Presence - Seeking Alpha 03.11.12 | 07:03 am
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO - Seeking Alpha 09.12.10 | 09:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress - Fox Business 08.16.10 | 12:08 pm
